Arthneeti

Smruthi Organics Share Price & Earnings Call Analysis

₹142.10+2.49% today
Market cap
₹163 Cr
P/E
20.49
ROE
5.17%
PEG
-6.47
Price to sales
1.46
Debt to equity
0.11
52W high / low
₹169 / ₹96.5
Sales growth (5Y)
-4.22%
EBITDA margin
16.68%
Net profit margin
3.68%
Promoter holding
64.73%
Sales (last year)
₹112 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Smruthi Organic rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Smruthi Organic.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Smruthi Organic

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Smruthi Organic

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +36.7834.9129.5923.4839.6627.2729.3931.2538.0918.9931.6022.2929.09
Expenses +34.5330.2925.1624.6635.5826.8226.5027.0833.4118.7626.5918.2925.30
Operating Profit2.254.624.43-1.184.080.452.894.174.680.235.014.003.79
OPM %6.12%13.23%14.97%-5.03%10.29%1.65%9.83%13.34%12.29%1.21%15.85%17.95%13.03%
Other Income +0.050.010.000.000.060.000.010.000.080.090.01-0.440.01
Interest0.250.330.390.320.370.410.440.510.520.460.660.250.31
Depreciation1.241.241.381.451.591.291.331.371.501.411.511.671.75
Profit before tax0.813.062.66-2.952.18-1.251.132.292.74-1.552.851.641.74
Tax %14.81%25.49%22.56%-22.03%30.73%-26.40%31.86%35.37%18.61%-29.03%27.72%14.63%38.51%
Net Profit +0.692.292.07-2.291.52-0.920.781.482.23-1.102.061.401.07
EPS in Rs0.602.001.81-2.001.33-0.800.681.291.95-0.961.801.220.93

Financials of Smruthi Organic

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +77747997137131126133141128126102
Expenses +726369941211169811513111611489
Operating Profit5111031715291810121213
OPM %6%14%13%3%12%12%23%14%7%9%10%13%
Other Income +00101411000-0
Interest654443111122
Depreciation544444445666
Profit before tax-623-5101224144555
Tax %-33%55%39%-31%30%30%29%25%8%28%27%27%
Net Profit +-412-37817104443
EPS in Rs-3.340.631.39-2.826.027.4114.959.073.613.143.113.00
Dividend Payout %0%0%0%0%11%14%20%33%55%48%48%0%

Financials of Smruthi Organic

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital444444111111111111
Reserves262728253339495657586062
Borrowings +453733312816103612178
Other Liabilities +343520253730211832372322
Total Liabilities1091038585101889288106118112104
Fixed Assets +353230303032313337404547
CWIP111120112133
Investments000000000000
Other Assets +726954546956605366776453
Total Assets1091038585101889288106118112104

Financials of Smruthi Organic

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +9149512212321241022
Cash from Investing Activity +-10-0-3-4-5-37-10-7-11-9
Cash from Financing Activity +-8-14-9-2-5-17-7-12-231-12
Net Cash Flow-1-0002-113-30-0-01
Free Cash Flow7138171719-43-4-214
CFO/OP184%128%93%159%71%160%101%33%136%46%100%182%

Financials of Smruthi Organic

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10395979597686278961179469
Inventory Days12316614512692751009196150151228
Days Payable1061281231301209781509814485111
Cash Conversion Cycle1201331199268468011893123160186
Working Capital Days28177832529973949285
ROCE %0%9%10%-1%21%25%39%21%7%8%8%8%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Aarti Drugs (Q2 FY27)

    826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals